Blink

I only blink once...then never again

[Blink @blinkx90]

$ALLR these are the tea leaves that you got to read..great point

[Ceazar @Ceazar_Black]

$ALLR When a clinical stage biotech is buying back their own shares that should tell you a thing or two...especially when they're taking on debt to do so. I'm sitting pretty.. yeah I might have to wait a day a week or a month I don't care I have what I need and adding

Yes this is an open label trial.. those who know know 😉

[Blink @blinkx90]

@MofeekS That is true and along the way I would typically expect a raise so one might have to moderate their expectations to the 100 to 200 dollar range but anything is possible

[Blink @blinkx90]

$ALLR sometimes you hear targets it's like this and you shake your head.. this is one of those times where the math actually works out..
Assuming ph2 goes and FDA is cool w registration on that...if SCLC as well absolutely can be min $7-10B mkt cap which is close to 600/shr

[Bio/Tech @BioTechCash]

$ALLR
BEST IN CLASS IN BILLION $$$ MKT
$24M MKT CAP & TRADES AT CASH
MAKE IT MAKE SENSE
$300/SHR IS FAIR NOTHING LESS

[Blink @blinkx90]

$ALLR ASCO 26 is at end of May.. Wonder if we see them there.. last time they attended was in 23..

[Blink @blinkx90]

$ALLR I expect this in a month or 2 to be over 1.60-2 min prob more..this is obvious to anyone who can read a chart and the way it has been basing these past few weeks.. this is so primed

[Bio/Tech @BioTechCash]

$ALLR Remember Mid 26 interim data..id say May is definitely close to "Mid-2026" expect runup to begin..those waiting entry might not have that much a chance at these prices too much longer..

Remember shareholder meeting is in a few weeks...

https://t.co/PKTPUxxscn

[Blink @blinkx90]

$ALLR

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Love this story!

“Three times, the company came within a week of running out of cash.”

Congrats to the @KeloniaTx team and investors for persevering!

[Blink @blinkx90]

$ALLR

The parallels are eerie

https://t.co/NPJRJZJKiS

[Blink @blinkx90]

$ALLR DRP is so underappreciated.. it can easily be a $250m+ technology on its own. The 320k Rev this q imo is just the beginning.

[WTec @WTec78]

@MetalBiotech @resveratrol67 $ALLR 10k 2026 page 3
18-granted and 9- pending

[Blink @blinkx90]

$ALLR if you missed this thread take a look. Yes, I believe we are sitting on gold.

[Ceazar @Ceazar_Black]

$ALLR Something I've never done b4... a master thread of all diligence related to Allarity. Bookmark this.

Past management vs now:

[Blink @blinkx90]

$ALLR One of the fascinating things about this slide which I've seen before is that it really is best in class especially with this maturing data both from a safety, tolerability, and efficacy standpoint.. and don't forget the VA already saw this over 9 months ago..

[Ceazar @Ceazar_Black]

$ALLR
BEST IN CLASS

[Blink @blinkx90]

$ALLR can someone pls give ME $20M at 5-9%??? What a crazy deal

I bet they disclosed something to Streeterville under NDA..Just too good

🔥🔥🔥🔥🔥

[Blink @blinkx90]

$ALLR One of the oldest tells in the book... Isreal basher/Iran promoter is usually a sign of low intelligence..they are automatic block

[Bio/Tech @BioTechCash]

$ALLR another clown.. seems like he's moved on to bashing Israel..dumber just gets dumber.. seems like that's where all the losers go today..not surprised

[Blink @blinkx90]

$ALLR honestly I have no idea how Thomas was able to pull up these terms.. I think it only shows the strength of their asset.. incredible..

[Ceazar @Ceazar_Black]

$ALLR wow this deal.. cash to 28 🔥🔥

"Financing Structured as Non-Convertible Debt Financing"

+$10m+10m

I really like this..

Waiting for the SEC filing to come out but everything I've seen the PR looks amazing wow I don't know how Thomas got these terms wow

~$35m cash

[Blink @blinkx90]

$ALLR especially in @DrMakaryFDA approach where ph3 shouldn't be necessary with a solid ph2..

[Ceazar @Ceazar_Black]

$ALLR depends on the FDA.. breakthrough would help.. again everything depends on the data.. but they have mentioned several times that the are looking for this to be(The ovarian at least)a pivotal/registrational trial.. considering that late stage ovarian is very tough I'd be inclined to agree

[Blink @blinkx90]

$ALLR and they lit added like $5B mkt cap on this when that announced last yr we r sitting on gold

[Bio/Tech @BioTechCash]

$ALLR and Corcepts was combo trial w dirty chemo and only added like an extra 4 ms vs reg chemo which was like 12 months here we have monotherapy w min side effects

[Blink @blinkx90]

$ALLR the deals keep on coming..

[Adam Feuerstein ✡️ @adamfeuerstein]

BREAKING: $GILD to acquire $ACLX for $7.8 billion, or $115 per share.

Centerpiece of deal: Anito-cel CAR-T therapy for multiple myeloma.

Full story here:

https://t.co/10TuDYFDfG

[Blink @blinkx90]

$ALLR I play the long game..I will win.

[Blink @blinkx90]

$ALLR Allarity story but terminal/4chan style I like it

[Ceazar @Ceazar_Black]

$ALLR

> be Allarity in the eyes of the market
> still priced like the old mess
> but the company you are looking at now is structurally different
> and the CEO is running it like a compressed-timeline value creation exercise

> start with the basics
> ~$16M cash
> zero debt
> one class of common shares
> no warrant overhang except a tiny amount at very high strikes
> no toxic preferred stack
> no variable price death spiral nonsense

> this matters because in microcap biotech the cap table is usually the product
> here the product is the product

> enter Thomas Jensen
> walks into a real cleanup job
> and instead of telling fairy tales about 2030 he does the boring lethal stuff first
> cleans shop
> terminates anything that does not drive near-term shareholder value
> cuts waste
> cuts programs
> stops the bleeding

> burn quickly goes from ~1.4M per month to ~0.5M per month
> capex discipline
> lean ops
> no empire building
> one focus

> then he upgrades execution talent
> brings in Jeremy Graff PhD(Eli Lilly Oncology 16+ yrs/serial biotech entrepreneur)
> serious oncology experience
> not a resume ornament
> a signal that this is being run for outcomes

> now zoom out
> the company still raises small amounts sometimes
> but not with penny warrants
> not with toxic structures
> not with “financing as a lifestyle”
> it is controlled runway management

> and the key point
> the lead asset is funded through the next real inflection
> stenoparib into the data readout window

> people forget what market we are in
> PARP inhibitors are still not just a major category, but a growing one too
> expected to be $11-13B by 2030
> big money already validated the class

> the question is not “does PARP work”
> the question is “is this one differentiated enough to matter”

> stenoparib checks multiple differentiation boxes
> remarkably well tolerated compared to other PARPis and definitely compared to chemo
> oral pill
> quality of life matters in late stage disease
> fatigue shows up but the typical marrow toxicity profile looks meaningfully cleaner than peers

> and then the big one
> crosses the blood brain barrier
> most PARPis do not meaningfully do that
> brain mets and CNS involvement are where drugs go to die
> a brain-penetrant PARP is not a normal feature

> another big one
> activity is not limited to BRCA positive
> most people do not have BRCA mutations
> broadening beyond BRCA is where the real population is
> and it also changes the valuation math if the signal holds

> now look at the patient context
> these are not first-line patients
> multi-line(some even w 5+ lines of treatment)
> chemo (Platinum refractory resistant)
> prior PARPis like olaparib and niraparib
> prior Elahere in some cases
> “standard options exhausted” population

> and stenoparib still produces durable benefit
> this is the part the market keeps hand-waving away
> but durable benefit in refractory ovarian is the entire game

> so why is Jensen zeroing in on late-stage ovarian specifically
> because this is where “short term” in biotech actually exists
> short term in biotech means months to a year
> not 5 years

> ovarian late stage has bad options
> the bar for meaningful differentiation is lower than people want to admit
> and the FDA has precedent for approvals off strong phase 2 data in high unmet need settings

> notice the language and design choices
> this is not framed like a casual phase 2b
> phase 2b implies “cool story, see you in phase 3”
> this is being positioned like a registrational intent trial
> pivotal-minded
> dose work plus efficacy signal
> built to support a regulatory conversation

> and yes the current FDA/Makary posture matters
> less interest in dragging timelines when the signal is real
> more interest in efficiency when endpoints and populations make sense
> that aligns with Jensen’s playbook

> FDA notices
> adds the Fast Track layer
> fast track based on extreme durability signals in a population that often ends in hospice quickly(3-4 months left)
> when you can point to durable responses in a setting where survival is measured in months
> the FDA listens

> compare what the market rewards
> corcept relacorilant shows around a ~4 month benefit versus standard chemo
> stock adds 5 billion in market cap on that kind of incremental improvement
> the lesson is clear
> the market pays for even modest clinical deltas

> meanwhile other ovarian options
> immunotherapy combos and other regimens
> IV infusion
> meaningful side effects
> quality of life tradeoffs
> a well tolerated oral agent is not a small thing in this population, esp in monotherapy w/o chemo

> now address the “some patients didn’t do well” argument
> yes variability exists
> that is exactly why dose selection matters
> when you examine the dataset, BID dosing stands out
> the long duration responders are disproportionately in the BID cohort
> cohort 2 in the company’s framing
> and the dramatic early response example shows what the top end can look like

> practical dosing thesis
> 200mg morning + 400mg evening appears directionally correct from the responder cluster
> open question is whether 400mg + 400mg is needed or tolerable
> FDA Project Optimus forces dose exploration and justification
> start lower
> escalate rationally
> optimize benefit-risk

> this is not a bug
> this is how you design a near-term registrational path in 2026

> then there is the IP and durability of value
> patent expiry baseline around 2032
> but DRP-linked biomarker strategy can extend commercial defensibility for way longer
> because the value is not only the molecule
> it is molecule + selection engine

> which brings us to DRP
> the market treats DRP like a footnote
> it is not a footnote
> it is a separate asset with its own optionality
> and it is exactly the kind of thing that can create non-linear value if validated in a pivotal setting

> now the VA moment
> Veterans Administration is building a trial in SCLC
> originally niraparib in the design
> a billion-dollar PARPi
> and they switch to stenoparib!

> that is not retail speculation
> that is an external institution looking at tolerability, rationale, and fit in a chemo combo setting
> and deciding stenoparib is the better tool

> and then the real gift
> fully funded 166 patient study
> company provides drug product
> VA funds the rest
> 30-40M equivalent value of clinical execution you did not have to pay for
> another real shot on goal with asymmetric economics

> now address the 6M raise question head-on
> if you do simple math
> burn ~0.5M per month
> 12 months is ~6M
> ovarian trial cost roughly ~10M if you assume ~250k per patient for ~40 patients
> so why raise at all

> because public companies live and die by “going concern” language
> they need to show runway
> ideally 12 months plus
> and management prefers to avoid being forced into financing from weakness

> so the raise reads less like “we are running out of money”
> and more like “we are extending runway through 2027 so we control the timeline”

> and if the structure is no warrants and VWAP-tied
> the optimal execution is obvious
> do it into strength
> do it on a catalyst day
> do it when volume is massive
> let the VWAP be pulled upward by real demand
> raise the small amount without poisoning the cap table(say it goes to $5 raise ~1.25m shares at $4.75, almost nothing), no way he's doing it down here..

> this is Jensen’s entire pattern
> short term value creation
> timeline compression
> capital structure discipline
> don’t trade upside for survival financing

> and the punchline
> we have a clean cap table microcap biotech
> with a funded lead program into a real readout window
> in a validated drug class
> with tolerability differentiation
> Oral, no intravenous
> Monotherapy in ovarian, no chemo necessay
> BBB penetration differentiation
> activity beyond BRCA positive
> late-stage ovarian as the fastest regulatory path
> Fast Track as validation
> VA-funded SCLC as free upside
> DRP as a separate long-dated optionality layer

> market still pricing the ghost of the old company

> Jensen is running the rebuilt company like time is the asset
> and he is locked in on the only thing that matters
> months-to-a-year value inflection
> not a 5-year science project
> so yes, im buying this at below cash

[Blink @blinkx90]

$ALLR imo ramp up to begin ~march/april

[Ceazar @Ceazar_Black]

$ALLR
FYI
Runway into 2027 with first substantive clinical data expected mid 2026.

[Blink @blinkx90]

$ALLR loving this chart. Every bit of it... poised for launch